Visceral Adipose Tissue and Ectopic Fat Deposition

Handbook of Obesity: Epidemiology, Etiology, and Physiopathology: Volume 1, Third Edition

Volumn 1, Issue , 2014, Pages 237-248

  Gastaldelli, Amalia ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947275377     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16473-26     Document Type: Chapter

References (100)

1. Shen W, Wang Z, Punyanita M, et al. Adipose tissue quantification by imaging methods: A proposed classification. Obes Res 2003;11:5-16.
2. Thomas EL, Parkinson JR, Frost GS, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ecto-pic fat. Obesity 2012;20:76-87.
3. Wald D, Teucher B, Dinkel J, et al. Automatic quantification of subcutaneous and visceral adipose tissue from whole-body magnetic resonance images suitable for large cohort studies. J Magn Reson Imaging 2012;36:1421-34.
4. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: The Framingham Heart Study. Circulation 2008;117:605-13.
5. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study. Eur Heart J 2009;30:850-6.
6. Sironi AM, Petz R, De Marchi D, et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med 2012;29:622-7.
7. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
8. Gastaldelli A, Sironi AM, Ciociaro D, et al. Visceral fat and beta cell function in non-diabetic humans. Diabetologia 2005;48:2090-6.
9. Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: Influence on insulin resistance and beta-cell function. Hypertension 2004;44:127-33. Epub 2004 Jul 19.
10. Alvehus M, Buren J, Sjostrom M, et al. The human visceral fat depot has a unique inflammatory profile. Obesity 2010;18:879-83.
11. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999;48:10-4.
12. Ferrannini E, Sironi AM, Iozzo P, et al. Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk. Eur Heart J Suppl 2008;10:B4-10.
13. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506.
14. Kotronen A, Yki-Jarvinen H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vac Biol 2008;28:27-38.
15. Iacobellis G, Ribaudo MC, Assael F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: A new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003; 88:5163-8.
16. Kotronen A, Juurinen L, Tiikkainen M, et al. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008;135:122-30.
17. Le KA, Ventura EE, Fisher JQ, et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011;34:485-90.
18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
19. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012;142:711-25 e6.
20. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008;47:51-8.
21. Hwang JH, Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: In vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 2007;293:E1663-9.
22. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: Normalisation of beta cell function in asso-ciation with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.
23. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: Structure, foetal devel-opment and biochemical properties. Comp Biochem Physiol B 1989;94:225-32.
24. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care 2011;34 Suppl 2:S371-9.
25. Reingold JS, McGavock JM, Kaka S, et al. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: Reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab 2005;289:E935-9.
26. Nakazato R, Rajani R, Cheng VY, et al. Weight change modulates epicardial fat burden: A 4-year serial study with non-contrast computed tomography. Atherosclerosis 2012;220:139-44.
27. Iacobellis G, Singh N, Wharton S, et al. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008;16:1693-7.
28. Willens HJ, Byers P, Chirinos JA, et al. Effects of weight loss after bariatric surgery on epicardial fat measured using echo-cardiography. Am J Cardiol 2007;99:1242-5.
29. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008;52:1006-12.
30. Kim MK, Tomita T, Kim MJ, et al. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol 2009; 106:5-11.
31. Schejbal V. [Epicardial fatty tissue of the right ventricle-morphology, morphometry and functional significance]. Pneumologie 1989;43:490-9.
32. Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: A new method for visceral adipose tissue prediction. Obes Res 2003;11:304-10.
33. Sacks HS, Fain JN. Human epicardial fat: What is new and what is missing? Clin Exp Pharmacol Physiol 2011;38:879-87.
34. Iozzo P, Lautamaki R, Borra R, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009;94:4472-82.
35. Korosoglou G, Humpert PM, Ahrens J, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging 2012; 35:804-11.
36. Zechner R, Kienesberger PC, Haemmerle G, et al. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res 2009;50:3-21.
37. Watt MJ, Spriet LL. Triacylglycerol lipases and metabolic control: Implications for health and disease. Am J Physiol Endocrinol Metab 2010;299:E162-8.
38. Albu JB, Curi M, Shur M, et al. Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity. Am J Physiol 1999;277:E551-60.
39. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
40. Heni M, Machann J, Staiger H, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: A nuclear magnetic resonance study. Diabetes Metab Res Rev 2010;26:200-5.
41. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93:S57-63.
42. Arner P. Insulin resistance in type 2 diabetes: Role of fatty acids. Diabetes Metab Res Rev 2002;18 Suppl 2:S5-9.
43. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-87.
44. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:92-103.
45. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005;54:1640-8.
46. Wang XL, Zhang L, Youker K, et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 2006;55:2301-10.
47. Chinen I, Shimabukuro M, Yamakawa K, et al. Vascular lipotoxicity: Endothelial dysfunction via fatty-acid-induced reac-tive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007;148:160-5.
48. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49:1939-45.
49. Watanabe S, Tagawa T, Yamakawa K, et al. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vac Biol 2005;25:2376-80.
50. Egan BM, Hennes MM, Stepniakowski KT, et al. Obesity hypertension is related more to insulin’s fatty acid than glucose action. Hypertension 1996;27:723-8.
51. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50:1612-7.
52. Brehm A, Krssak M, Schmid AI, et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 2006;55:136-40.
53. Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002;51:2005-11.
54. Liu GX, Hanley PJ, Ray J, et al. Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circ Res 2001;88:918-24.
55. Guerrero R, Vega GL, Grundy SM, et al. Ethnic differences in hepatic steatosis: An insulin resistance paradox? Hepatology 2009;49:791-801.
56. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009;106:15430-5.
57. Gastaldelli A, Miyazaki Y, Pettiti M, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002;87:5098-103.
58. Sunny NE, Parks EJ, Browning JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-10.
59. Boden G, Chen X, Capulong E, et al. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001;50:810-6.
60. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: A quantitative study. Diabetes 2000;49:1367-73.
61. Gastaldelli A, Miyazaki Y, Pettiti M, et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 2004;89:3914-21.
62. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and car-diovascular risk factors in obese adults. Gastroenterology 2010;139:448-55.
63. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005;48:634-42.
64. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-504.
65. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-80.
66. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
67. Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver index is associated with insulin resistance, risk of coronary heart disease and early atherosclerosis in a large European population. Hepatology 2009;49:1537-44.
68. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191: 391-6.
69. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11:1848-53.
70. Aygun C, Kocaman O, Sahin T, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thick-ness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008;53:1352-7.
71. Brea A, Mosquera D, Martin E, et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vac Biol 2005;25:1045-50.
72. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.
73. van der Zijl NJ, Goossens GH, Moors CC, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: Impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011; 96:459-67.
74. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: Evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002;51:1437-42.
75. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-74.
76. Lee Y, Lingvay I, Szczepaniak LS, et al. Pancreatic steatosis: Harbinger of type 2 diabetes in obese rodents. Int J Obes 2010;34:396-400.
77. Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: A 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999;48:1600-6.
78. Szendroedi J, Roden M. Mitochondrial fitness and insulin sensitivity in humans. Diabetologia 2008;51:2155-67.
79. Moro C, Bajpeyi S, Smith SR. Determinants of intramyocellular triglyceride turnover: Implications for insulin sensitivity. Am J Physiol Endocrinol Metab 2008;294:E203-13.
80. van Loon LJ, Goodpaster BH. Increased intramuscular lipid storage in the insulin-resistant and endurance-trained state. Pflugers Arch 2006;451:606-16.
81. Cogswell AM, Stevens RJ, Hood DA. Properties of skeletal muscle mitochondria isolated from subsarcolemmal and inter-myofibrillar regions. Am J Physiol 1993;264:C383-9.
82. Nielsen J, Mogensen M, Vind BF, et al. Increased subsarcolemmal lipids in type 2 diabetes: Effect of training on localization of lipids, mitochondria, and glycogen in sedentary human skeletal muscle. Am J Physiol Endocrinol Metab 2010;298:E706-13.
83. Hoppeler H, Fluck M. Plasticity of skeletal muscle mitochondria: Structure and function. Med Sci Sports Exerc 2003;35:95-104.
84. Corradi D, Maestri R, Callegari S, et al. The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. Cardiovasc Pathol 2004;13:313-6.
85. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: Anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-43.
86. Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ Res 2009;104:541-9.
87. Snel M, Jonker JT, Hammer S, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity 2012;20:1572-6.
88. Ding J, Kritchevsky SB, Harris TB, et al. The association of pericardial fat with calcified coronary plaque. Obesity (Silver Spring) 2008;16:1914-9.
89. Djaberi R, Schuijf JD, van Werkhoven JM, et al. Relation of epicardial adipose tissue to coronary atherosclerosis. Am J Cardiol 2008;102:1602-7.
90. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007;13:2180-4.
91. Kankaanpaa M, Lehto HR, Parkka JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: Relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006;91:4689-95.
92. Lamb HJ, Smit JW, van der Meer RW, et al. Metabolic MRI of myocardial and hepatic triglyceride content in response to nutritional interventions. Curr Opin Clin Nutr Metab Care 2008;11:573-9.
93. Winhofer Y, Krssak M, Jankovic D, et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid con-tent in normal subjects. Diabetes 2012;61:1210-6.
94. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 2010;88:229-40.
95. Neglia D, De Caterina A, Marraccini P, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H3270-8.
96. Aghamohammadzadeh R, Withers S, Lynch F, et al. Perivascular adipose tissue from human systemic and coronary ves-sels: The emergence of a new pharmacotherapeutic target. Br J Pharmacol 2012;165:670-82.
97. Meijer RI, Serne EH, Smulders YM, et al. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 2011;11:211-7.
98. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: A mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817-20.
99. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, et al. Perivascular adipose tissue as a messenger of the brain-vessel axis: Role in vascular inflammation and dysfunction. J Physiol Pharmacol 2007;58:591-610.
100. Eringa EC, Bakker W, van Hinsbergh VW. Paracrine regulation of vascular tone, inflammation and insulin sensitivity by perivascular adipose tissue. Vascul Pharmacol 2012;56:204-9.